These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 2875864)

  • 21. [Treatment of peptic ulcer with histamine H2 receptor antagonists].
    Domschke W; Domschke S; Demling L
    Fortschr Med; 1977 Aug; 95(31):1899-902. PubMed ID: 19347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacology of famotidine.
    Smith JL
    Digestion; 1985; 32 Suppl 1():15-23. PubMed ID: 2866132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical importance of the new H2-antagonists.
    Walt RP
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():97-9. PubMed ID: 2566730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Vinayek R; Hahne WF; Euler AR; Norton JA; Jensen RT
    Dig Dis Sci; 1993 Oct; 38(10):1857-65. PubMed ID: 8104773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter, randomized, double-blind study comparing famotidine with ranitidine in the treatment of active duodenal ulcer disease.
    McCullough AJ
    Am J Med; 1986 Oct; 81(4B):17-24. PubMed ID: 2877570
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders.
    Spencer CM; Faulds D
    Drugs; 1994 Sep; 48(3):404-30. PubMed ID: 7527761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Omeprazole in the therapy of acid-induced diseases].
    Simon B; Dammann HG; Müller P
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.
    Grant SM; Langtry HD; Brogden RN
    Drugs; 1989 Jun; 37(6):801-70. PubMed ID: 2667937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What are the differences between the H2-receptor antagonists?
    Schunack W
    Aliment Pharmacol Ther; 1987; 1 Suppl 1():493S-503S. PubMed ID: 2908767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of peptic ulcer in the Zollinger-Ellison syndrome with histamine H2-receptor antagonists (author's transl)].
    Hausamen TU; Fritsch WP; Scholten T; Jungblut R; Strohmeyer G
    Dtsch Med Wochenschr; 1977 Nov; 102(47):1709-12. PubMed ID: 21785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Strong inhibition of gastric acid secretion: when is it justifiable?].
    Dobrilla G; Amplaz S; Benvenuti S; Bertozzo A
    G Clin Med; 1990; 71(8-9):521-6. PubMed ID: 1980653
    [No Abstract]   [Full Text] [Related]  

  • 32. Role of acid suppressants in patients with Zollinger-Ellison syndrome.
    Maton PN
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():25-35. PubMed ID: 1679671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers.
    Meijer JL; Jansen JB; Lamers CB
    Digestion; 1989; 44 Suppl 1():31-9. PubMed ID: 2575060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.
    Lambers CB; Lind T; Moberg S; Jansen JB; Olbe L
    N Engl J Med; 1984 Mar; 310(12):758-61. PubMed ID: 6142418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A case of refractory chronic Zollinger-Ellison syndrome--treated successfully with famotidine].
    Shiratori K; Watanabe S; Maruyama M; Adachi H; Itoh Y; Kurokawa K; Takeuchi T
    Nihon Shokakibyo Gakkai Zasshi; 1984 Jul; 81(7):1623-7. PubMed ID: 6149326
    [No Abstract]   [Full Text] [Related]  

  • 36. Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease.
    Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1978 Feb; 15(2):93-131. PubMed ID: 342231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
    McTavish D; Buckley MM; Heel RC
    Drugs; 1991 Jul; 42(1):138-70. PubMed ID: 1718683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of famotidine on hepatic hemodynamics and peptic ulcer.
    Ohnishi K; Saito M; Nomura F; Okuda K; Suzuki N; Ohtsuki T; Goto N; Takashi M
    Am J Gastroenterol; 1987 May; 82(5):415-8. PubMed ID: 2883883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [25 years of gastric acid blockers].
    Lamers CB
    Ned Tijdschr Geneeskd; 1999 Dec; 143(50):2501-4. PubMed ID: 10627749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histamine H2-receptor antagonists and gastric acid secretion -- a progress report.
    Black JW
    Klin Wochenschr; 1976 Oct; 54(19):911-4. PubMed ID: 10467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.